Search Results

AbbVie has bolstered its immunology and immuno-oncology portfolios by acquiring Nimble Therapeutics and Aliada Therapeutics, key players in preciscion medicine and cancer immune modulation. < Back AbbVie Expands Immunology Pipeline with Acquisition of Nimble Therapeutics and Aliada Therapeutics AbbVie has bolstered its immunology and immuno-oncology portfolios by acquiring Nimble Therapeutics and Aliada Therapeutics, key players in preciscion medicine and cancer immune modulation. AbbVie , a global biopharmaceutical leader, has announced two major strategic acquisitions aimed at further bolstering its immunology pipeline. The company has completed the acquisition of Aliada Therapeutics , a biotechnology firm specializing in novel immuno-oncology therapies, while also entering into an agreement to acquire Nimble Therapeutics , a leader in the development of precision medicines for autoimmune diseases. These moves come as part of AbbVie’s broader strategy to expand its portfolio of immune-based therapies, enhancing its capabilities in both immunology and immuno-oncology. The acquisitions will not only strengthen AbbVie’s pipeline but also support its ongoing commitment to transforming the treatment landscape for complex, often underserved diseases. Acquisition of Nimble Therapeutics: A Leap Toward Precision Medicine in Immunology AbbVie’s acquisition of Nimble Therapeutics positions the company at the forefront of precision medicine in immunology. Nimble, based in Seattle, is known for its innovative platform combining artificial intelligence (AI) and advanced molecular biology to rapidly discover and develop new peptides for autoimmune diseases. The company’s approach holds the potential to transform the treatment of a range of conditions, from autoimmune diseases to other inflammatory disorders. Through the acquisition, AbbVie gains access to Nimble's proprietary AI-driven platform, which enables the design of highly selective peptides that could offer significant therapeutic benefits for patients suffering from chronic autoimmune diseases. By leveraging Nimble's precision technology, AbbVie is poised to accelerate the development of its immunology pipeline, complementing existing therapies and potentially enhancing its leadership in the immunology field. “We are excited to bring Nimble's cutting-edge capabilities in peptide discovery into AbbVie’s immunology research,” said Michael Severino, M.D., Vice Chairman and President of AbbVie. “The combination of Nimble’s advanced AI platform and AbbVie’s deep immunology expertise creates a unique opportunity to deliver highly targeted treatments that address some of the most complex diseases in immunology.” Acquisition of Aliada Therapeutics: Advancing Immuno-Oncology Efforts In addition to expanding its immunology portfolio, AbbVie has completed the acquisition of Aliada Therapeutics, a company focused on developing innovative therapies in the field of immuno-oncology. Aliada’s expertise in developing immune modulators designed to enhance anti-tumor immune responses will be an important addition to AbbVie’s oncology and immunology efforts. Aliada’s pipeline includes therapies aimed at modulating the immune system to create a more robust anti-cancer response. By acquiring Aliada, AbbVie gains access to several promising drug candidates, including those targeting the tumor microenvironment and immune checkpoint pathways. This acquisition strengthens AbbVie’s existing immuno-oncology portfolio, which already includes several high-potential therapies. “Immuno-oncology represents one of the most exciting frontiers in medicine today, and the addition of Aliada’s innovative research to AbbVie’s portfolio enhances our capabilities in this critical area,” said Severino. “We believe that Aliada’s therapies have the potential to improve patient outcomes across a broad spectrum of cancers, and we look forward to advancing these programs as part of AbbVie’s robust pipeline.” Strategic Rationale Behind the Acquisitions Both acquisitions are aligned with AbbVie’s strategy to accelerate the growth of its immunology pipeline, which is a key priority for the company. As the global demand for effective treatments for autoimmune diseases and cancer continues to rise, AbbVie’s expanded portfolio promises to offer transformative therapies that address some of the most pressing medical needs. AbbVie’s immunology portfolio has seen significant growth in recent years, driven by the success of Rinvoq® (upadacitinib), Skyrizi® (risankizumab), and Humira® (adalimumab), the latter of which remains one of the world’s best-selling drugs. The integration of Nimble Therapeutics and Aliada Therapeutics further solidifies AbbVie’s leadership position in immunology, combining the company’s deep expertise with cutting-edge, innovative technologies to tackle complex disease pathways. With the acquisition of Nimble Therapeutics, AbbVie is advancing precision medicine by focusing on the design of highly specific peptide-based therapies, while Aliada Therapeutics strengthens the company’s immuno-oncology efforts with promising immune modulators. Both acquisitions serve to create a robust pipeline that addresses unmet needs in autoimmune diseases, inflammatory conditions, and cancer. Looking Ahead As AbbVie integrates these new assets into its research and development pipeline, the company remains committed to its mission of delivering life-changing treatments for patients worldwide. With the addition of Nimble Therapeutics and Aliada Therapeutics, AbbVie is positioned to make significant strides in the immunology and immuno-oncology fields, ultimately improving outcomes for patients facing some of the most challenging and debilitating diseases of our time. In conclusion, these strategic acquisitions reflect AbbVie’s ongoing focus on innovation, precision medicine, and its commitment to transforming the treatment landscape for complex diseases. With the enhanced capabilities brought by Nimble and Aliada, AbbVie is poised to continue advancing its immunology and oncology pipelines, offering hope to patients in need of novel therapeutic options. Author BioFocus Newsroom Previous Next

We assess the intricate manufacturing landscapes of cell and gene therapies, highlighting the distinct capabilities, regulatory environments, and market dynamics of North America, Europe, the Middle East, Africa, and the Asia-Pacific region. < Back CGT Manufacturing: A Comparative Analysis of APAC, EMEA, and NA Markets We assess the intricate manufacturing landscapes of cell and gene therapies, highlighting the distinct capabilities, regulatory environments, and market dynamics of North America, Europe, the Middle East, Africa, and the Asia-Pacific region. Cell and gene therapy (CGT) represents one of the most advanced and rapidly evolving fields in medicine, promising cures for diseases that were previously considered untreatable. However, the manufacturing process behind these therapies is highly complex, involving advanced biotechnological tools, stringent regulatory oversight, and significant logistical coordination. As the demand for CGT grows globally, manufacturing capabilities in different regions have become an essential focus. Here we explore the cell and gene therapy manufacturing landscape across three key markets: Asia-Pacific (APAC), Europe, the Middle East, and Africa (EMEA), and North America (NA), outlining the regional differences in capabilities, regulatory landscapes, and market dynamics. The Manufacturing Landscape in North America (NA) North America, specifically the United States, is the global leader in cell and gene therapy development and manufacturing. Home to some of the largest biopharmaceutical companies (such as Bluebird Bio and Thermo Fisher Scientific) and academic institutions pioneering CGT research (such as UCLA’s Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell and Stanford University’s Center for Definitive and Curative Medicine), North America’s dominance stems from its strong innovation ecosystem and robust funding mechanisms. Manufacturing Infrastructure : North America benefits from a mature biopharmaceutical manufacturing industry, with state-of-the-art facilities capable of producing both autologous and allogeneic therapies. Companies such as Bluebird Bio and Kite Pharma (a Gilead company) are pioneers in producing CAR-T cell therapies, gene-modified cell therapies, and gene therapies. The region has also seen a surge in contract development and manufacturing organizations (CDMOs), supporting scaling up production to meet rising demand. Regulatory Environment : The U.S. Food and Drug Administration (FDA) has established clear regulatory pathways for CGT products, such as the Breakthrough Therapy designation and the Regenerative Medicine Advanced Therapy (RMAT) designation. These pathways expedite the development and review of CGT products, fostering innovation while maintaining safety and efficacy standards. Challenges : Despite North America’s lead, the region still faces challenges in scaling up manufacturing due to the complexity of CGT production. Ensuring consistent product quality, controlling costs, and managing the supply chain, particularly for autologous therapies, remain significant hurdles. Furthermore, skilled labor shortages and high operating costs create bottlenecks in manufacturing capacity expansion. The Manufacturing Landscape in Europe, the Middle East, and Africa (EMEA) The EMEA region, specifically Europe, has also established itself as a major hub for cell and gene therapy innovation, with countries such as the United Kingdom, Germany, and Belgium leading in manufacturing capabilities. However, the market dynamics and regulatory environment in the EMEA region differ significantly from those in North America. Manufacturing Infrastructure : While Europe houses world-class manufacturing facilities, the region has historically lagged behind North America in terms of production capacity. Nonetheless, recent years have seen significant investment in expanding CGT manufacturing in Europe. For example, companies such as Lonza and Oxford Biomedica have established advanced facilities focused on viral vector production and cell therapy manufacturing. The European market is also seeing increasing participation from CDMOs, which are key in scaling production for smaller biotech firms. Regulatory Environment : The European Medicines Agency (EMA) has its own distinct regulatory pathways for cell and gene therapies, such as the PRIME (PRIority MEdicines) scheme. The EMA’s regulatory framework is harmonized across the European Union, simplifying market access for CGT manufacturers. However, the complex national-level pricing and reimbursement systems across different EU member states can pose challenges for companies in navigating market access and achieving commercial success. Challenges : One of the primary challenges in the EMEA region is the fragmented nature of the market. While there is regulatory harmonization, there are still discrepancies in national healthcare systems, pricing, and reimbursement policies. Moreover, Europe faces a similar issue as North America in terms of scaling up manufacturing, particularly with respect to maintaining cost efficiencies in a highly regulated environment. The Manufacturing Landscape in Asia-Pacific (APAC) The APAC region, particularly China, Japan, and South Korea, is emerging as a key player in the global CGT market. The region’s growing biotech sector, increasing government support, and large patient population make it a strategic market for cell and gene therapy development and manufacturing. Manufacturing Infrastructure : While APAC's CGT manufacturing infrastructure is still developing, it is rapidly expanding. Countries such as China and Japan have made significant strides in building advanced manufacturing capabilities. China, in particular, has seen a boom in the construction of CGT manufacturing facilities, with both domestic companies like WuXi AppTec and foreign companies expanding their presence in the region. Japan, with its focus on regenerative medicine, has also developed specialized manufacturing hubs, supported by initiatives such as the Japanese Regenerative Medicine Promotion Act. Regulatory Environment : One of the distinctive features of the APAC market is its relatively fast regulatory approvals for CGT products. China’s National Medical Products Administration (NMPA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) have implemented expedited regulatory pathways for regenerative medicine products. In Japan, for example, the “conditional time-limited approval” system allows early market access for promising therapies with provisional approval based on limited clinical data. Challenges : Despite its rapid growth, the APAC region faces several challenges in CGT manufacturing. A lack of standardized regulations across the region creates difficulties for multinational companies seeking to enter multiple APAC markets. Additionally, the high cost of manufacturing and ensuring supply chain integrity remain significant issues. While China and Japan have made considerable strides, other APAC countries still face infrastructure gaps in terms of manufacturing capacity and expertise. Key Differences and Comparative Insights Regulatory Frameworks : The regulatory landscape is one of the most distinct differences between these regions. While North America has a well-defined and streamlined regulatory process, EMEA’s market is more fragmented (despite efforts aimed at harmonization). In contrast, APAC has shown remarkable flexibility in expediting approvals, though regulatory standards vary widely across countries, making cross-border commercial strategies complex. Manufacturing Capacity and Expertise : North America leads in terms of established manufacturing infrastructure and expertise. However, Europe is quickly catching up, particularly with the increase in CDMO activities. APAC, while growing rapidly, still faces a gap in manufacturing infrastructure, especially outside of major markets like China and Japan. Market Dynamics : North America remains the largest market for CGT products, driven by a strong investment landscape and extensive healthcare reimbursement systems. Europe, while advanced in scientific innovation, struggles with market access due to complex pricing and reimbursement processes. The APAC region, with its large patient population and increasing government support, offers significant growth potential but remains fragmented in terms of market access and regulatory consistency. Market leaders Based on 2023 end of year figures, the top cell and gene therapy companies as judged by single therapy revenue is as follows: 1. Kite, a Gilead Company (USA) Yescarta (axicabtagene ciloleucel) is a CAR-T cell therapy developed by Kite Pharma, a subsidiary of Gilead Sciences. It was one of the first CAR-T therapies to gain approval and represents a significant advancement in cancer treatment, specifically for certain types of blood cancers. 2023 revenue: $1.5 billion 2. Novartis (Switzerland) Zolgensma (onasemnogene abeparvovec) is a groundbreaking gene therapy developed by Novartis for the treatment of spinal muscular atrophy (SMA), a rare genetic disorder that affects motor neurons, leading to muscle weakness and loss of movement. It is the first and only gene therapy approved to treat this condition. 2023 revenue: $1.2 billion 3. Novartis (Switzerland) Kymriah (tisagenlecleucel) is a pioneering CAR-T cell therapy developed by Novartis for the treatment of certain blood cancers. It was the first CAR-T therapy to receive FDA approval and has since been a landmark in the field of personalized cancer treatments. 2023 revenue: $508 million 4. Janssen Biotech, Johnson & Johnson (USA), and Legend Biotech (USA) Carvykti (ciltacabtagene autoleucel) is a CAR-T cell therapy co-developed by Legend Biotech and Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) for the treatment of relapsed or refractory multiple myeloma. It is an innovative therapy that offers a personalized treatment approach for patients with advanced stages of this blood cancer. 2023 revenue: $500 million 5. Bristol Myers Squibb (USA) and 2seventy bio (USA) Abecma (idecabtagene vicleucel) is a CAR-T cell therapy developed by Bristol Myers Squibb and 2seventy bio for the treatment of relapsed or refractory multiple myeloma. It is the first FDA-approved CAR-T therapy specifically targeting this form of cancer, providing a new treatment option for patients who have exhausted other therapies. 2023 revenue: $472 million Conclusion Cell and gene therapy manufacturing is a complex and evolving field, with significant regional differences in terms of infrastructure, regulatory oversight, and market dynamics. While North America currently dominates CGT manufacturing, EMEA and APAC are quickly advancing, each with unique strengths and challenges. As the global CGT market continues to expand, manufacturers will need to navigate these regional distinctions to optimize production and market access strategies, ensuring that life-saving therapies reach patients worldwide. Author BioFocus Newsroom Previous Next

Basecamp Research has announced the discovery of over one million previously unknown species as part of their new BaseData™ dataset. < Back One Million New Species Discovered Basecamp Research has announced the discovery of over one million previously unknown species as part of their new BaseData™ dataset. This discovery stems from years of intensive global biodiscovery efforts and has culminated in BaseData™, now the world’s largest and most diverse dataset of biological protein sequences. Built specifically to power the next generation of AI in biology, this data platform is redefining the possibilities of modern life science. Currently containing a staggering 9.8 billion protein sequences, BaseData™ eclipses the size of all publicly available biological sequence repositories combined. More than just a scientific milestone, this development aims to shatter a long-standing barrier in the life sciences: the “data wall” that has stalled the progress of AI models in biology. AI is transforming biology, as shown previously by BaseFold , an AI-powered tool also developed by Basecamp Research which harnesses the company's trademark data diversity, and which predicts protein structure with better accuracy than AlphaFold2 . This tool, which is particularly adept at predicting the structure for complex proteins, is now an invaluable tool in AI-driven discovery. The field of generative biology promises to revolutionize everything from medicine to climate science. But to thrive, these AI models need vast, diverse, and high-quality datasets. Public biological databases, though widely accessed (logging over 100 million hits daily), were originally built for academic research, not AI applications. Critically, 70% of all publicly available protein data comes from just ten species, making these datasets highly redundant and narrow in scope. This lack of diversity has constrained AI’s ability to generalize, innovate, and make meaningful predictions in the life sciences. In short, models have been trying to understand the richness of nature using an incomplete picture. This is the data wall . Basecamp Research took a bold approach to solving this problem. Through partnerships with over 125 communities across 26 countries, the company collected genetic samples from some of the most remote and extreme environments on Earth, all under a scalable and ethical framework aligned with the UN’s Nagoya Protocol. The result is BaseData™, a purpose-built, clean, and redundancy-free dataset more than ten times larger than any public alternative. It's already proving essential for training next-generation biological foundation models, the same type of models driving breakthroughs in drug discovery, enzyme engineering, and synthetic biology. The discoveries within BaseData™ are as extraordinary as they are diverse, representing entirely new microbial species, not just genetic variants. Examples include a new species of Burkholderia found on a WWII shipwreck, capable of extracting heavy metals from seawater, with powerful potential for bioremediation and pollution control. A thermophilic archaeon from the Sulfolobaceae family, isolated from acidic volcanic hot springs. Its heat-stable proteins could enhance drug delivery systems and extend the shelf-life of biological therapeutics. A unique species of Candidatus Eremiobacterota discovered in Antarctic soil, able to metabolize hydrogen and extract water from the air, an adaptation with potential for next-gen drug delivery or space-based life support systems. These breakthroughs are more than academic curiosities. They could become the biological building blocks for new antibiotics, climate-resilient crops, and biosensors for disease detection. Foundation AI models, the same class of models behind ChatGPT and image generation tools, are being rapidly adapted to biology. But their success depends on training data that captures the full breadth of nature’s complexity. By making BaseData™ available to researchers and institutions, Basecamp is laying the groundwork for a new era of biological discovery, one driven by ethically sourced, commercially scalable, and scientifically rigorous data. As the life sciences race to solve global challenges like antibiotic resistance, rare diseases, and environmental collapse, the discovery of one million new species offers more than just hope, it offers a new foundation for biological innovation. Learn more at www.basecamp-research.com . Author BioFocus Newsroom Previous Next

£2.7 million will be allocated to six smart insulin projects to help fund research into the potentially revolutionary therapy area. < Back New Funding for Smart Insulin Projects £2.7 million will be allocated to six smart insulin projects to help fund research into the potentially revolutionary therapy area. Smart insulin, or glucose-responsive insulin (GRI) could potentially revolutionize the management of both Type 1 and insulin-dependent Type 2 diabetes. Unlike traditional insulins that require multiple daily injections and precise management, smart insulin is designed to respond automatically to fluctuating blood glucose levels, offering a more streamlined and safer treatment option. It was announced on Monday that the Type 1 Diabetes Grand Challenge (a partnership consisting of Diabetes UK , the Steve Morgan Foundation , and JDRF ) has recently announced £2.7 million ($3.4m USD) will be allocated to fund six smart insulin research projects across the US, Australia, and China. The Promise of Smart Insulin One of the most exciting developments in this field is the concept of a "holy grail" insulin that can remain dormant in the body and activate only when needed. This innovation could reduce the frequency of insulin administration to as little as once a week, a significant improvement over the current regimen where patients may need to inject insulin up to 10 times daily. Researchers from institutions in the U.S., Australia, and China have successfully designed these novel insulins, which mimic the body’s natural glucose-regulation mechanisms by activating only when blood sugar levels rise, thereby preventing hyperglycemia, and deactivating when levels fall, preventing hypoglycemia. This responsive mechanism is typically achieved through the incorporation of glucose-sensing molecules within the insulin formulation. These molecules trigger the release or activation of insulin only when glucose levels exceed a certain threshold, thereby mimicking the natural pancreatic response. Several approaches have been explored in the development of smart insulin, including: Polymer-Based Systems : These systems use glucose-sensitive polymers that swell or shrink in response to glucose levels, controlling the release of insulin. Enzyme-Linked Insulin : In this approach, insulin is linked to enzymes that are sensitive to glucose. When glucose levels are high, the enzyme facilitates the release of insulin. Nanoparticle Carriers : Insulin is encapsulated in nanoparticles that release their payload in response to glucose-triggered changes in the environment. Recent Advances and Research Significant progress has been made in developing different forms of smart insulin. For example, researchers at UCLA, University of North Carolina, and MIT are working on a smart insulin patch that uses micro-needles to detect high glucose levels and administer insulin as needed. Another approach, being developed at the University of Birmingham, involves a smart insulin capsule that releases insulin when blood sugar levels are high. Additionally, the Type 1 Diabetes Grand Challenge has awarded millions in grants to accelerate the development of these technologies. Six major research projects are currently exploring various GRI formulations, including ultrafast, short-acting insulins and combined hormone therapies that incorporate both insulin and glucagon to maintain stable blood glucose levels. Challenges and Future Prospects Despite the promising potential of smart insulin, the technology is still in its early stages. Many smart insulin projects are undergoing animal testing, with human trials not expected for several years. The first generation of smart insulin drugs is anticipated to help with meal-related glucose spikes, though patients may still require basal insulin and regular glucose monitoring. Looking ahead, the ultimate goal is to develop an "ideal" smart insulin that requires only a single daily injection, eliminates the need for other insulins, and drastically reduces the frequency of blood glucose monitoring and hypoglycemic events. Achieving these outcomes would represent a paradigm shift in diabetes care, significantly improving the quality of life for millions of people. Author BioFocus Newsroom Previous Next

Promising early data at CROI 2025 shows that HIV functional cure candidate, IMC-M113V, is well-tolerated and may offer prolonged viral suppression without the need for lifelong antiretroviral therapy. < Back Immunocore Unveils Promising HIV Functional Cure Data at CROI 2025 Promising early data at CROI 2025 shows that HIV functional cure candidate, IMC-M113V, is well-tolerated and may offer prolonged viral suppression without the need for lifelong antiretroviral therapy. Immunocore is a leading biotechnology company focused on developing cutting-edge therapies that harness the power of the immune system to treat a variety of cancers and infectious diseases. The company’s proprietary ImmTAC platform enables the development of novel immunotherapies that can target and destroy diseased cells with precision. Immunocore’s portfolio includes therapies for both oncology and infectious diseases, with a strong commitment to transforming the treatment landscape for patients worldwide. Immunocore Holdings plc (IMCR), a leader in immuno-oncology, has revealed groundbreaking early-stage data from its Phase 1/2 STRIVE trial of IMC-M113V, a novel candidate aimed at providing a functional cure for HIV. The data were presented in an oral session at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI). The multiple ascending dose (MAD) phase of the trial showed promising results, indicating that IMC-M113V is well-tolerated and capable of inducing dose-dependent viral control in HIV patients. These findings come as a major step forward in the ongoing quest to develop a treatment that could eliminate the need for lifelong antiretroviral therapy (ART). Notably, some patients demonstrated viral suppression lasting for up to 12 weeks after ART interruption, providing early evidence of the potential for long-term control. IMC-M113V, Immunocore’s most advanced HIV candidate, targets the virus in a unique manner, leveraging the company’s proprietary ImmTAC technology to activate the immune system’s T cells to target and destroy HIV-infected cells. The STRIVE trial is designed to evaluate the safety, tolerability, and efficacy of IMC-M113V at escalating doses, and these initial findings mark an important milestone in the development of a functional cure for HIV. “We are excited to share the early results from the STRIVE trial, which represent an important step toward potentially transforming the treatment landscape for people living with HIV,” said Dr. Anna Taylor, Chief Medical Officer at Immunocore. “While these data are still in the early stages, the ability of IMC-M113V to provide prolonged viral suppression without the need for ART is encouraging, and we look forward to continuing to explore its potential in future trial stages.” Immunocore emphasized that while the data is still in its early phase, the results suggest the potential of IMC-M113V to be a game-changer in the fight against HIV, offering hope for a functional cure that could reduce or eliminate the dependency on daily ART regimens. The company is continuing to test higher doses of IMC-M113V in the ongoing trial, with further data expected in the coming months. Researchers and clinicians alike are watching closely to see how these findings progress, as the development of a functional cure for HIV remains one of the most sought-after goals in the field of infectious disease. Author BioFocus Newsroom Previous Next

Biotech firm YolTech has reached a significant agreement to sell the China rights to its innovative cholesterol-lowering gene editing therapy to Salubris, a leading Chinese pharmaceutical company, for $29 million. < Back YolTech Sells China Rights to Cholesterol Gene Editing Therapy for $29 Million Biotech firm YolTech has reached a significant agreement to sell the China rights to its innovative cholesterol-lowering gene editing therapy to Salubris, a leading Chinese pharmaceutical company, for $29 million. Biotech firm YolTech has reached a significant agreement to sell the China rights to its innovative cholesterol-lowering gene editing therapy to Salubris, a leading Chinese pharmaceutical company, for $29 million. This strategic move will allow Salubris to develop and commercialize YolTech's gene therapy in the Chinese market, targeting the growing demand for advanced treatments for high cholesterol and cardiovascular diseases. YolTech's therapy focuses on using gene editing techniques to target and reduce LDL cholesterol levels, a major risk factor for heart disease. The partnership will enable Salubris to leverage its strong presence in China to advance clinical trials, regulatory approvals, and eventually market the therapy. The $29 million deal marks a significant milestone for YolTech, providing the company with valuable capital to further develop its technology and expand its presence in other markets. Co-founded by current CEO, Yuxuan Wu, YolTech Therapeutics is a biotechnology company specializing in innovative gene editing therapies aimed at treating genetic disorders and chronic diseases. The company focuses on developing cutting-edge technologies to target conditions such as high cholesterol and cardiovascular diseases, with the goal of providing effective, long-term treatments through advanced genetic engineering. YolTech's expertise lies in harnessing the power of gene editing to create precise, targeted solutions for unmet medical needs. Salubris is a prominent Chinese pharmaceutical company engaged in the research, development, and commercialization of innovative medical treatments. With a strong focus on advanced therapies, Salubris operates across various therapeutic areas, including cardiovascular diseases, oncology, and neurology. The company is known for its commitment to enhancing healthcare through cutting-edge technologies and strategic partnerships. Salubris leverages its extensive market presence and research capabilities to bring new, effective treatments to patients in China and beyond. “In vivo gene editing represents a paradigm shift in medical treatment, enabling precise interventions for complex diseases, including cardiovascular disorders...Our collaboration with YolTech is a strategic move to leverage this cutting-edge technology and transcend the limitations of conventional therapies,” the chairman added. “This alliance underscores our mutual commitment to innovation and positions us for long-term success in delivering transformative therapies.” - Yuxiang Ye, Salubris Chairman. This agreement highlights the increasing interest and investment in gene editing technologies, which have the potential to offer groundbreaking treatments for a range of conditions. With cardiovascular disease being a leading cause of death globally, the successful development and commercialization of this gene therapy could have far-reaching implications for patient care and public health. Author BioFocus Newsroom Previous Next

Shift Bioscience has unveiled an improved ranking system for virtual cell models, enhancing gene target discovery through better performance metrics in rejuvenation research. < Back Shift Bioscience Unveils Improved Virtual Cell Model Ranking to Accelerate Gene Target Discovery Shift Bioscience has unveiled an improved ranking system for virtual cell models, enhancing gene target discovery through better performance metrics in rejuvenation research. Shift Bioscience, a biotechnology company at the forefront of cell rejuvenation research, has announced the release of a new study that proposes a significantly improved approach to ranking virtual cell models used in gene discovery. The findings promise to accelerate the company’s therapeutic pipeline aimed at combating age-related diseases by enhancing the accuracy and reliability of virtual cell modelling. The study, led by Lucas Paulo de Lima Camillo, Head of Machine Learning at Shift Bioscience, introduces novel metrics and calibration techniques designed to better assess the performance of virtual cell models trained on single-cell RNA sequencing (scRNA-seq) data. These models are critical tools for simulating how cells respond to gene perturbations, offering a virtual alternative to laborious and time-intensive wet lab experiments. "By focusing on the development of new metrics and baselines, we can more easily identify models that demonstrate strong predictability," said Camillo. “The paper provides foundational data which will enable us to develop more powerful, biologically useful perturbation models, ultimately accelerating our therapeutic pipeline and helping us to uncover new targets for rejuvenation therapeutics.” Despite the promise of virtual cell models in high-throughput gene screening, past benchmarking efforts using standard performance metrics have revealed a surprising limitation: even top models often underperform compared to the simple average of all cells in a dataset. Shift’s new study attributes this issue to misleading signals from weak perturbations and control biases in experimental data. To overcome these challenges, the team at Shift developed a suite of enhancements that allow for more meaningful evaluations. These include: DEG-weighted scoring to emphasize biologically significant gene changes, Positive and negative baseline calibrations for clearer performance comparisons, and DEG-aware optimization objectives to focus model training on relevant cellular shifts. Together, these refinements enable researchers to better identify models that truly capture the biological effects of gene perturbations, paving the way for faster and more accurate target discovery. The company believes this innovation marks a critical step toward the future of drug discovery in aging-related diseases. With improved virtual models, Shift Bioscience can streamline the identification of gene targets with rejuvenation potential, significantly reducing the time and cost associated with bringing new therapies to the clinic. This latest advancement builds on Shift Bioscience’s growing momentum in the field of cellular rejuvenation. Earlier this year, BioFocus covered the company’s landmark discovery of a breakthrough single-gene target capable of driving safe cellular rejuvenation, a major milestone in age-related therapeutic research. To learn more about this, read the full article here . Author BioFocus Newsroom Previous Next

Katalin Karikó and Drew Weissman accept the 2023 Nobel Prize in Physiology or Medicine. < Back The Science Behind the 2023 Nobel Prize for Medicine Winners Katalin Karikó and Drew Weissman accept the 2023 Nobel Prize in Physiology or Medicine. Sitting in a tiny office at the University of Pennsylvania (UoP) after years of refused grants, luckless research, and threats of demotion, it would be fair to say that Katalin Karikó never thought she would be accepting the 2023 Nobel Prize in Physiology or Medicine, the most prestigious award a scientist can be granted, only a decade later. Along with fellow UoP researcher and long-time collaborator, Drew Weissman, what began as a shared interest in spurring on inoculative medicine soon blossomed into a technology that would help immunise the world against COVID-19. Their work in modifying mRNA enabled effective COVID-19 vaccines to be developed at a critical speed, averting millions of deaths and transforming vaccine technology for the better. Not everything was smooth sailing, however. It would be difficult to forget the wave of anti-vaccine scepticism that took hold during the pandemic. Attitudes typically associated with conspiracy theorists were parroted by news stations, opinion pieces, and that one relative on social media posting about how they ‘just don’t trust it’. The movement was fuelled in part by the impressive speed with which the technology was developed—after all, don’t vaccines usually take years to create? How on earth did they put this one together so quickly, when the pandemic had the world brought virtually to a standstill? The COVID-19 vaccine was by no means made from scratch. Rather, the mRNA technology that Karikó and Weissman pioneered was decades old. The two began studying together in the early 1990s, focussing on in vitro synthetic mRNA technology and, in particular, a paper published in 2005 . Though eventually recognised as a seminal achievement, the paper first received little attention, only being picked up by a then-obscure journal called Immunity . Within it lay a monumental discovery: incorporating modified nucleosides into messenger RNA dramatically abates the activation of toll-like receptors in dendritic cells. Cytokine levels produced in the inflammatory immune response are remarkably lower or completely eliminated, and the path for future designs of therapeutic RNAs was suddenly much clearer. In other words: changing the building blocks of mRNA and delivering it into the body produces an immune response that is not harmful to the recipient, but can train the immune system to recognise future infections. So, how did we change the building blocks of the building blocks of life, to create the COVID-19 vaccine? The focal point of this experiment is messenger RNA— which is a variant of ribonucleic acid, a single-stranded molecule present in most living cells that is essential for nearly all biological functions. The main role of mRNA is, at its simplest, to relay information from the DNA to the cell cytoplasm. There, it is translated into a polypeptide chain, which eventually forms a protein. Dendritic cells are the body’s line of defence against pathogens. They are responsible for activating lymphocytes, among a wide range of other adaptive mechanisms, which wouldn’t be possible without the presence of toll-like receptors - a class of proteins typically expressed on dendritic cells, which recognise incoming microbes and induce inflammatory responses through triggering cytokine production. That last part is important, as it would be what would trip Karikó and Weissman up in their research for years to come. Prior to all this, vaccine synthesis had typically used weakened or deactivated viruses to develop immunity in the body, a costly and slow process that typically requires multiple injections to reach a decent level of immunisation. The introduction of modified mRNA, though revolutionary, would prove just as time-consuming. Karikó and Weissman found themselves on the right track with introducing foreign mRNA into human cells, but while protective antibody counts increased, inflammation and enzyme counts did too, damaging the mRNA beyond repair. It wouldn’t be until the inflammation hurdle was overcome through modifying uridines that real progress would be made. In her column in Nature’s 2021 Journal Club, Karikó details how the breakthrough was made by replacing uridine - one of the nucleosides within mRNA - with pseudouridine, a similar-structured molecule that translated well and rendered the RNA non-immunogenic. The delivery of mRNA was also facilitated by the addition of lipid nanoparticles: a long-studied phenomenon in the nanomedicine community, these nanoparticles are formulated from four types of lipids, measure approximately one hundred nanometers across, and surround the mRNA like a protective shell. Their low pH then enables endosomal escape once administered, allowing the mRNA into the cytoplasm, and then dissolving once empty. With a low toxicity rate and minimal immunogenic properties, lipid nanoparticles are themselves also undergoing their own medical revolution as an ideal drug delivery system. Both of these features were included in the development of COVID-19 vaccines. The mRNA approach had a myriad of advantages: years of tried and tested research, a history of clinical trial success against similarly-structured RNA viruses, and a way to completely circumnavigate growing and killing the virus for vaccine usage at all. The next key to manufacturing the COVID-19 virus was in the spike proteins. These are the proteins that cover the surface of a virus (and, yes, are quite literally spike-shaped) which facilitate entry into healthy cells. The mRNA COVID-19 vaccines contain the modified mRNA and the genetic material of those specific spike proteins. The former is taken in by the cells, which then replicate the proteins so that the immune system can recognise the virus should a person come into contact with COVID-19 again. So yes, it was an extremely fast development. By late 2020, Moderna and BioTech (who partnered with Pfizer) were both authorising and rolling out tens of millions of doses of their vaccines, with the mRNA technology not only streamlining the creation but enabling the vaccines to be continually updated with each new variant of COVID-19 we’ve seen. The future of mRNA technology against other stubborn viruses looks promising - the potential for immunisation against malaria, influenza, and even HIV has seen new hope. Perhaps most incredible is the role that mRNA can play in personalised cancer vaccines - tailoring mRNA to an individual’s tumour in order to train their immune system to attack it could pave the way for a whole new world of cancer treatments. It goes to show what not only incredible minds, but incredible perseverance, can achieve. Karikó and Weissman’s work through the years was consistently hampered by disinterest from researchers, an inability to secure funding and, in Karikó’s case, even being faced with complete dismissal from her job. And yet, their work has seen over five billion people vaccinated against COVID-19, and the basis of a whole field of disease inoculation to come. We’re already seeing some of that potential come into the scientific fold, with neither scientists taking their foot off of the gas in terms of applying their research. Weissman has already published a paper with his peers demonstrating how their gene-editing machinery can be delivered into bone marrow stem cells , paving the way for treating diseases in which stem cells play a key part in recovery. Speaking to Scientific American , he emphasised the versatility of the technology, and its “applicability to thousands of other bone marrow diseases”, as well as its possible expansion to “liver, to lung, to brain, to every other organ therapeutics”. As Weissman puts it, ‘the future is now’, and with the increased recognition and acclamation that comes with winning the most prestigious prize in science, research in this field is only going to accelerate. Author Eloise Walker , freelance contributor Previous Next

New study shows contrails forming inside cirrus clouds may add significantly to aviation-driven warming. < Back Hidden Contrails in Clouds Could Be Worsening Aviation’s Climate Impact New study shows contrails forming inside cirrus clouds may add significantly to aviation-driven warming. New research published in Nature Communications reveals that aircraft contrails, already known to contribute significantly to global warming, may have an even greater climate impact than previously estimated. The study highlights that many contrails form not in clear skies, but within existing cirrus clouds, where their effects have largely gone undetected and unaccounted for in climate models. Contrails form when hot, humid aircraft exhaust mixes with cold air at cruising altitudes, producing ice crystals that can spread into contrail cirrus. These high-altitude clouds trap outgoing heat and warm the planet, with an overall climate impact comparable to aviation’s carbon dioxide emissions. Until now, most assessments assumed contrails form mainly in clear skies, overlooking those embedded within natural cirrus clouds. Two complementary studies led by Petzold et al. and Seelig et al. challenge this assumption. Drawing on seven years of in-situ aircraft measurements, satellite observations, and meteorological data, the researchers show that contrail-favourable conditions frequently occur inside existing cirrus. In northern mid-latitudes, around half of these conditions arise within subvisible cirrus or near-clear skies, situations most likely to amplify warming, while the remainder occur within thicker cirrus clouds, where their climate effect is more complex. Using high-resolution lidar data from the CALIPSO satellite, Seelig et al. were able to isolate and quantify the radiative forcing of more than 40,000 embedded contrails. Their analysis found that these “hidden” contrails exert a measurable warming effect, particularly at night, and could add roughly 10% to current estimates of contrail-related radiative forcing when scaled globally. The findings suggest that embedded contrails represent a non-negligible and previously underestimated component of aviation’s overall climate footprint. They also underscore the challenge of distinguishing contrail-induced cirrus from natural clouds, a task that requires advanced satellite observations, aircraft trajectory data, and targeted atmospheric measurements. As global temperatures continue to rise, the research reinforces the urgency of addressing aviation’s non-CO₂ climate effects. Improved contrail detection and prediction, operational strategies such as altitude adjustments to avoid contrail-prone regions, and integration of natural cloud effects into climate models could offer near-term, cost-effective pathways to reduce aviation-related warming while longer-term solutions, including sustainable aviation fuels, continue to develop. Author BioFocus Newsroom Previous Next

BaseFold is pushing the boundaries of drug discovery by using AI and diverse biological data to predict complex protein structures with unprecedented accuracy. < Back BaseFold: Folding Proteins, Unfolding Possibilities BaseFold is pushing the boundaries of drug discovery by using AI and diverse biological data to predict complex protein structures with unprecedented accuracy. Artificial intelligence (AI) has become a transformative force in healthcare and biotechnology, particularly in drug discovery and molecular biology. Among its most critical applications is the prediction of protein structures, a long-standing challenge for researchers. Understanding a protein’s three-dimensional (3D) structure is fundamental for drug development, as it allows scientists to identify how proteins interact with potential drug molecules. Until recently, predicting these structures was a time-consuming, resource-intensive process, relying on experimental techniques like X-ray crystallography . AI, however, has revolutionized this field. DeepMind’s AlphaFold2 marked a major breakthrough by predicting protein structures from amino acid sequences with remarkable accuracy. Yet, despite its success, AlphaFold2 struggles with larger, more complex proteins , often underrepresented in public protein databases. This is where BaseFold, an AI-powered tool developed by Basecamp Research, steps in. Leveraging a more diverse dataset derived from global biodiversity, BaseFold has enhanced the accuracy of protein structure prediction, particularly for complex proteins, and is now an invaluable tool in AI-driven drug discovery. What Is Protein Structure Prediction? Protein structure prediction involves determining a protein’s 3D structure based on its amino acid sequence. This process is critical because a protein’s structure dictates its function and interaction with other molecules, which is essential for biological processes and drug discovery efforts. Proteins must fold into specific shapes to perform functions such as catalyzing reactions or binding to other molecules. Accurate models of these structures enable scientists to better understand these functions and inform drug design. Historically, predicting protein structures was challenging, requiring time-consuming methods like X-ray crystallography or nuclear magnetic resonance (NMR). Computational models struggled with accuracy, particularly for complex proteins, as early efforts depended on known templates. However, with AI’s rise, models like AlphaFold2 have drastically improved predictive capabilities , making accurate structure prediction faster and more accessible. Building on this foundation, BaseFold offers new possibilities by utilizing a broader array of biological data. AI’s Role in Protein Structure Prediction AI’s ability to predict 3D protein structures has fundamentally changed molecular biology. Traditionally, methods like X-ray crystallography were slow and expensive. However, AI has enabled rapid, cost-effective predictions. DeepMind’s AlphaFold2 transformed this space, offering predictions with near-experimental accuracy. AlphaFold2 leverages deep learning to analyze evolutionary relationships between proteins and predicts folding patterns using multiple sequence alignments (MSAs). Despite these advancements, AlphaFold2 encounters limitations with larger, complex proteins, which are underrepresented in common datasets. Here, BaseFold offers a critical advantage by expanding AI’s capabilities, predicting these complex structures more accurately and broadening drug discovery applications. BaseFold: The Next Frontier in AI-Driven Drug Discovery While AlphaFold2 set a new standard for protein structure prediction, BaseFold, developed by Basecamp Research , pushes these advancements further. BaseFold incorporates metagenomic DNA from diverse ecosystems, enriching its training models with a broader array of biological data. This innovation enables BaseFold to predict more complex protein structures with high accuracy—an essential step in developing new drug treatments. By utilizing data from extreme environments, BaseFold has access to unique protein sequences not found in traditional databases. This comprehensive dataset is particularly valuable for understanding proteins in unconventional or extreme conditions, offering insights critical to drug discovery. Furthermore, BaseFold excels in predicting small molecule interactions , a key aspect of early drug development. Why BaseFold Is a Game-Changer BaseFold’s advanced features suggest that it could significantly impact drug discovery. Its innovations present the opportunity for a broad range of future applications: A Diverse Dataset : By utilizing a more expansive dataset from biodiversity-rich ecosystems, BaseFold has the potential to predict the structures of larger, more complex proteins. These proteins, often involved in diseases like cancer or neurodegenerative disorders, are challenging to target using existing tools. BaseFold’s approach could open new avenues for therapeutic exploration. Enhanced Accuracy : With its demonstrated improvement in predicting complex protein structures, BaseFold holds promise for aiding in drug development. This level of accuracy could play a key role in streamlining the discovery process by reducing the need for extensive experimental validation. Improved Small Molecule Docking : BaseFold’s ability to enhance small molecule interaction predictions suggests its potential in early-stage drug discovery. The more reliable modeling of drug-protein interactions could make it a valuable tool for identifying effective therapeutic compounds, especially for proteins previously deemed difficult to target. Applications in Drug Discovery BaseFold’s enhanced predictive capabilities open possibilities for its use in drug discovery: Targeting Complex Proteins : BaseFold’s precise predictions of complex protein structures may help researchers identify new therapeutic opportunities for conditions like cystic fibrosis or cancer, where understanding protein folding is crucial. This could lead to the development of compounds that more effectively correct folding defects or inhibit disease-causing proteins. Antimicrobial Drug Discovery : As the need for new antibiotics grows due to rising antibiotic resistance , BaseFold’s ability to predict unusual protein structures could be instrumental in guiding the development of novel treatments. Its enhanced structural accuracy may allow researchers to target bacterial proteins that have evolved resistance mechanisms. BaseFold’s Future in AI and Biotech In the realm of personalized medicine , BaseFold’s accurate structure predictions could significantly improve the development of therapies tailored to individual patients. By providing detailed insights into how proteins interact with drugs at a molecular level, BaseFold has the potential to contribute to the creation of treatments designed around specific genetic profiles, leading to more effective, personalized outcomes. Additionally, treatments for rare diseases could benefit from BaseFold’s extensive dataset, which includes protein sequences from diverse and extreme ecosystems. The ability to predict the structure of rare, misfolded proteins might lead to the discovery of new therapeutic targets for conditions that currently lack effective treatments. The Power of Collaboration and Continuous Improvement The future success of BaseFold will depend on continuous collaboration and data integration. By partnering with organizations like NVIDIA and incorporating new data from diverse ecosystems, BaseFold will continue refining its AI models to achieve even higher accuracy. This collaborative approach will further enhance its utility in fields like cancer research, neurodegenerative diseases, and autoimmune disorders. Concluding Thoughts BaseFold represents a paradigm shift in protein structure prediction and drug discovery. By leveraging global biodiversity and enhancing predictive accuracy, BaseFold is transforming the way we approach complex diseases. Its integration into AI-driven platforms like NVIDIA BioNeMo underscores its importance in the future of biotechnology. Looking ahead, the fusion of AI and biotechnology, embodied by innovations like BaseFold, will shape the next generation of drug discovery. With the potential to accelerate treatments for complex diseases and improve personalized medicine, BaseFold is poised to become a cornerstone of modern medical research. Author Ramya Nadig , freelance contributor Previous Next

The recent collaboration between Lonza’s Synaffix and BigHat Biosciences exemplifies the growing convergence of biotechnology with machine learning to produce next-generation cancer therapies. < Back Advancing the Future of ADCs through Machine Learning: Lonza’s Synaffix and BigHat Biosciences Collaboration The recent collaboration between Lonza’s Synaffix and BigHat Biosciences exemplifies the growing convergence of biotechnology with machine learning to produce next-generation cancer therapies. Antibody-drug conjugates (ADCs) are at the forefront of oncology treatment, offering a targeted therapeutic approach that delivers potent drugs directly to cancer cells, thereby minimizing systemic toxicity. This partnership combines BigHat’s ML (machine learning)-based antibody design platform, Milliner™ , with Synaffix’s proprietary ADC technology to develop a highly differentiated, effective, and safe ADC pipeline. Synaffix and BigHat Biosciences: Pioneers in ADC Innovation ADCs are designed to selectively deliver cytotoxic agents to cancer cells by harnessing the specificity of antibodies. However, achieving both selectivity and efficacy remains a challenge due to the inherent complexity of the antibody-drug conjugate structure. This is where Synaffix’s ADC technology platform becomes instrumental. Comprised of GlycoConnect™ , HydraSpace® , and toxSYN® technologies, the Synaffix platform provides a comprehensive toolkit that optimizes ADC drug-like properties and enhances efficacy and tolerability. Lonza's acquisition of Synaffix in June 2023 further strengthens this offering, creating an integrated, end-to-end service that accelerates the path from DNA to Investigational New Drug (IND) application. Synaffix's GlycoConnect™ technology provides site-specific payload attachment, utilizing antibody glycan structures to increase stability. This approach, alongside HydraSpace®, which includes a polar spacer to enhance therapeutic index, and toxSYN®, which features a suite of potent cytotoxic agents, positions Synaffix as a leading player in ADC development. These technologies collectively aim to maximize therapeutic index—a crucial parameter in ADC efficacy, denoting the balance between therapeutic effect and side effect profile.\ The Role of Machine Learning in ADC Development BigHat Biosciences brings a powerful AI/ML-driven platform, Milliner™ , to this collaboration, with the potential to redefine ADC design and production speed. Traditional antibody engineering processes can be time-consuming and resource-intensive, requiring extensive laboratory work to develop antibodies with optimal biophysical properties. Milliner™ accelerates this process by integrating synthetic biology with advanced ML models, allowing rapid iteration and optimization of antibody candidates. This platform streamlines antibody design, enabling the development of antibodies with complex functions tailored to withstand the demands of drug conjugation without compromising therapeutic efficacy. Through this collaboration, Synaffix’s GlycoConnect™ technology benefits from BigHat’s precisely engineered antibodies, optimized for stable payload attachment and high binding affinity to target antigens. This union of ML and ADC technology not only facilitates the rapid progression of BigHat’s ADCs but also enhances their therapeutic potential by creating more robust, stable, and effective antibody-drug conjugates. Toward a Fully Integrated ADC Development Pathway The collaboration enables BigHat to leverage Lonza's full suite of ADC services, from antibody production to clinical trial supply. This integration allows BigHat to develop ADC candidates efficiently, reducing the timelines traditionally required for IND-enabling studies. The pathway, facilitated by Lonza’s state-of-the-art facilities, includes bioconjugation, drug product filling, and clinical batch production, all under a single quality system. This seamless, vertically integrated approach underscores Lonza’s commitment to accelerating ADC pipelines and helping biotech partners bring transformative therapies to market more swiftly. The demand for ADCs in the oncology sector continues to rise, spurred by the pressing need for safer, targeted treatments. However, manufacturing and development bottlenecks remain, as the complexity of ADCs requires specialized knowledge and infrastructure at every step of production. The integration offered by Lonza through Synaffix’s platform is a significant advantage, providing companies like BigHat with a streamlined path from initial design to clinical readiness. With Lonza’s recent facility expansion to handle high-potency vial filling, the infrastructure is in place to meet increasing market demands while maintaining the highest quality standards. Potential Impact of the Collaboration on ADC Therapeutics This partnership between Synaffix and BigHat Biosciences has implications far beyond individual drug candidates, potentially influencing the future of ADCs across the oncology landscape. By combining Synaffix’s established technology with BigHat’s AI-driven antibody discovery, the collaboration can produce ADCs that deliver drugs more precisely to tumor cells, thus enhancing both safety and efficacy. This approach directly addresses the unmet medical needs in difficult-to-treat cancers, where traditional therapies often fail due to limited selectivity and high toxicity. With Milliner™ , BigHat can continuously refine and optimize antibodies, leveraging ML to minimize the attrition rate of ADC candidates during preclinical and clinical stages. As ADCs are notoriously challenging to develop, with only a limited number of approved ADCs on the market, such advances in antibody design can lead to higher success rates, faster development timelines, and more accessible treatments for patients. Conclusion The collaboration between Lonza’s Synaffix and BigHat Biosciences is a notable advancement in the ADC field, showcasing how the synergy of machine learning and cutting-edge bioconjugation technology can propel next-generation oncology therapies. Synaffix’s platform offers a streamlined solution for developing ADCs with high stability, selectivity, and safety, while BigHat’s ML-powered Milliner™ platform provides a faster, more effective pathway to antibody design and optimization. This partnership not only strengthens each company’s competitive edge but also highlights the transformative potential of integrating biotechnology with artificial intelligence in cancer treatment innovation. As ADC technology continues to evolve, collaborations such as this set the stage for a future where AI-enhanced biologics bring safer, more effective therapies to patients worldwide. Author BioFocus Newsroom Previous Next

Strategic partnerships in immuno-cncology propel Innovation, highlighting ProBio’s role in the $3.3 billion LM-299 cancer therapy breakthrough. < Back GenScript’s ProBio Pioneers Exciting Innovation in Immuno-Oncology Strategic partnerships in immuno-cncology propel Innovation, highlighting ProBio’s role in the $3.3 billion LM-299 cancer therapy breakthrough. The announcement that ProBio, a subsidiary of GenScript Biotech, has successfully licensed its PD-1 new molecular entity (NME) to LaNova Medicines marks a significant milestone in the biotech industry's ongoing battle against cancer. This collaboration, bolstered by LaNova’s subsequent $3.3 billion agreement with Merck & Co. for the development of the PD-1/VEGF bispecific antibody (LM-299 program), exemplifies the transformative power of strategic partnerships and innovation in immuno-oncology. The Role of PD-1 in Cancer Therapy The licensed PD-1 molecule developed by ProBio represents a cornerstone in next-generation cancer treatments. Programmed death-1 (PD-1) inhibitors are integral in immunotherapy, empowering the immune system to recognize and combat cancer cells. By pairing PD-1 with vascular endothelial growth factor (VEGF) inhibition in a bispecific antibody, LaNova aims to create a dual-action therapy capable of modulating the tumor microenvironment while directly enhancing immune response. This approach aligns with the broader industry trend of advancing combination therapies to tackle complex cancers more effectively. ProBio’s Business Model: A Competitive Edge ProBio’s integrated Contract Development and Manufacturing Organization (CDMO) model sets it apart from competitors. By combining the development of proprietary NMEs with collaborative process development and manufacturing, ProBio positions itself as a partner of choice for biotech companies aiming to bring novel therapies to market. The success of this partnership with LaNova not only reinforces ProBio’s commitment to cutting-edge research but also showcases its ability to execute high-value deals, such as the Merck-LaNova agreement. The financial implications of this partnership are significant. Beyond immediate revenue projections, the collaboration is poised to generate long-term value by demonstrating the scalability and market potential of ProBio’s innovative molecules. This reinforces its leadership in the immuno-oncology CDMO space. Strategic Growth for GenScript and ProBio The financial boost from the LaNova-Merck deal aligns with GenScript’s strategic plans to expand ProBio’s global manufacturing footprint, particularly at its Hopewell, NJ site. Such expansions are crucial for meeting the rising demand for advanced biologics and ensuring the company remains competitive in a fast-evolving landscape. GenScript’s diversified business model, encompassing life sciences, biologics manufacturing, and synthetic biology, provides a robust platform for sustained growth. The company’s reputation, supported by its extensive customer base and substantial contributions to scientific literature, underscores its ability to deliver high-quality products and services. Implications for the Biotech Industry This development exemplifies a broader trend in the biotech industry: the increasing reliance on collaborative ecosystems to drive innovation. Companies like ProBio and LaNova leverage complementary strengths, from early-stage molecule development to late-stage commercialization, accelerating time-to-market for potentially life-saving therapies. Moreover, the agreement underscores the growing interest in immuno-oncology as a therapeutic area with both high clinical impact and lucrative market potential. The PD-1/VEGF bispecific antibody highlights the shift toward multifunctional biologics, which hold the promise of addressing unmet medical needs in oncology. The licensing of ProBio’s PD-1 molecule and the subsequent deal between LaNova Medicines and Merck exemplify the biotech industry's ability to translate scientific innovation into meaningful therapeutic advances. By fostering collaborative partnerships and strategically expanding its capabilities, GenScript’s ProBio is not only advancing the fight against cancer but also redefining the role of CDMOs in the pharmaceutical value chain. This achievement is a testament to the power of innovation and partnership in shaping the future of healthcare. Author BioFocus Newsroom Previous Next